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The number of patients with autoimmune diseases and severe allergies and recipients of transplants increases worldwide. Currently,
these patients require lifelong administration of immunomodulatory drugs. Often, these drugs are expensive and show immediate
or late-occurring severe side effects. Treatment would be greatly improved by targeting the cause of autoimmunity, that is, loss of
tolerance to self-antigens. Accumulating knowledge on immune mechanisms has led to the development of tolerogenic dendritic
cells (tolDC), with the specific objective to restrain unwanted immune reactions in the long term. The first clinical trials with
tolDC have recently been conducted and more tolDC trials are underway. Although the safety trials have been encouraging, many
questions relating to tolDC, for example, cell-manufacturing protocols, administration route, amount and frequency, ormechanism
of action, remain to be answered. Aiming to join efforts in translating tolDC and other tolerogenic cellular products (e.g., Tregs and
macrophages) to the clinic, a European COST (European Cooperation in Science and Technology) network has been initiated—A
FACTT (action to focus and accelerate cell-based tolerance-inducing therapies). A FACTT aims tominimize overlap andmaximize
comparison of tolDC approaches through establishment of minimum information models and consensus monitoring parameters,
ensuring that progress will be in an efficient, safe, and cost-effective way.
1. The Case for Cell-Based
Therapy in Autoimmunity, Allergy,
and Transplantation
The healthy immune system is well balanced to protect
against invading harmful pathogens or cancerous cells, whilst
maintaining a state of unresponsiveness (“tolerance”) to
our self-tissues and harmless substances [1]. Breakdown of
immunological tolerance can lead to unwanted, detrimen-
tal reactions that cause autoimmune diseases (AID) like
rheumatoid arthritis (RA), type 1 diabetes (T1D), or multiple
sclerosis (MS) and allergies such as allergic asthma and
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Figure 1: Adoptive transfer of immunoregulatory function. Trans-
plantation of cells with immunoregulatory function to control
unwanted immune reactions is not a new proposition. From the
earliest discovery that transferring regulatory cells from tolerant to
nontolerant animals could establish tolerance in the recipient, it was
suggested that the same principle could be applied therapeutically
in man. However, while adoptive transfer became a common exper-
imental practice, its translation to the clinic met many obstacles,
not least the difficulty of identifying and isolating human regulatory
cells.
food allergies. These immune-mediated diseases are a major
disease burden. Worldwide, it is estimated that almost 1 in 10
individuals (7.6%–9.4%) [2] suffer from AID, and 1 in 9 have
a recorded diagnosis of allergy.
Rejection of allogeneic tissues and graft-versus-host dis-
ease (GvHD) are unwanted immune reactions that present
major barriers to successful solid organ and bone marrow
transplantation. Many factors influence reactivity to foreign
transplants, the most fundamental ones of which are graft
antigenicity and the contribution of alloreactive effector T
cells [3]. Unravelling the rules of donor-recipient histocom-
patibility has enabled tens of thousands of tissue, organ,
and stem cell transplantations to be performed in Europe
annually [4]. Nevertheless, as perfect matching of tissue-type
is not usually possible, most transplant recipients depend
upon lifelong generalised immunosuppression that primarily
targets T cells to prevent transplant rejection or GvHD [5].
Existing therapies to treat or prevent AID, allergy, and
transplantation reactions mostly include chronic treatment
with immunomodulatory drugs.These drugs however are not
curative and are inevitably associatedwith a risk of immediate
or late-occurring severe adverse effects (e.g., life-threatening
infections, cancer). In addition, general immunosuppressive
therapy may become ineffective over time as the physiology
of the patient changes (e.g., when neutralising antibodies
are induced against a biological agent), low-grade immune
reactions ensue, or the pathological mechanisms of disease
change under continuous therapeutic pressure. Application
and continued monitoring of these lifelong therapies repre-
sent an enormous economic burden for society and have a
dramatic impact on the quality of patients’ lives. Hence, there
is an unmet need for more effective and safer therapies aimed
at inducing or restoring immune tolerance [6].
The principle of adoptive transfer of immunological
function with purified populations of leucocytes has long
been known to experimental immunologists (Figure 1). From
the very earliest discovery of transferrable suppressor cell
populations in animals, it was proposed that cell transplan-
tation could be used as a tolerance-promoting therapy in
humans [7]. Recent scientific and technological advances
have enabled the identification, isolation, and ex vivomanip-
ulation of various types for use as therapeutic agents. The
development of cell-based therapies is clinically attractive
for many reasons, not least the prospect of low-toxicity
and antigen-specific therapies. More remarkably, because
immunological tolerance is a self-reinforcing state [8], the
therapeutic effects of cell therapy can outlive the therapeutic
cells themselves, opening the possibility of curative treat-
ments. Several cell types are now in early-stage clinical trials
as adjunct immunosuppressive agents, including various
types of regulatory T cells (Tregs) [9] or tolerogenic antigen-
presenting cells (including tolerogenic DC (tolDC) and regu-
latorymacrophages (Mregs)) [10–13]. At the present time, it is
unclear which of these cell types will prove most suitable as a
cell-based therapy; indeed, each has its particular advantages.
Here, we describe the collaborative efforts of the A FACTT
consortium to tackle the scientific, clinical, and regulatory
obstacles to the implementation of therapy with tolAPC.
2. Mononuclear Phagocytes and
the Maintenance of Peripheral Tolerance
Precisely to avoid the autoimmune and hypersensitivity
reactions described above, immunological responses must
be controlled at many levels. During their development,
T cells, B cells, and NK cells undergo selective processes
that limit their potential for self-reactivity; however, this
“central” tolerance alone does not fully account for nonre-
sponsiveness to self and innocuous foreign antigens. Many
cooperating mechanisms of “peripheral” tolerance have now
been described, including peripheral clonal deletion, anergy,
exhaustion, deviation, ignorance, and regulation. In the last 15
years, the preeminent role of active, cell-mediated regulation
has emerged from studies of regulatory cell populations,most
notably FoxP3+ Tregs. Subsequently, the dependence of T
cell-mediated regulation on tolAPC [14] became a subject of
intense research. It is now firmly established that specialised
subpopulations ofmononuclear phagocytes are indispensable
for the induction and maintenance of self-tolerance [15], as
well as preventing constitutive inflammation in response to
nonpathological stimuli [16].
Tolerogenic function is not limited to any particular sub-
set of mononuclear phagocytes; more confusingly, different
regulatoryDC andmacrophages subsets can act through sim-
ilar cellular andmolecularmechanisms. Reflecting on the role
of mononuclear phagocytes in the cycle of orderly inflamma-
tionmay help to explain this apparent redundancy (Figure 2).
Macrophages and DC are normal constituents of tissue
stroma, serving vital functions in maintaining tissue home-
ostasis by eliminating necrotic cells and suppressing inflam-
matory responses against innocuous stimuli. Under steady-
state noninflammatory conditions, tissue-resident DC also
migrate to lymphoid tissues via afferent lymphatics where
they contribute to the maintenance of peripheral T cell toler-
ance of self and other nonharmful antigens.Macrophages and
DC in tissues are exquisitely sensitive to pathogenic signals
from their environment, which drive their maturation to an
immunogenic state. Activation of mononuclear phagocytes
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Figure 2: Mononuclear phagocytes are vital for control of inflam-
matory responses. Mononuclear phagocytes are highly adaptable
effector cells that engage in diverse, often antagonistic processes: DC
and macrophages are capable of both stimulating or suppressing T
cell-mediated responses depending upon their state of activation.
Under normal physiological, noninflammatory conditions, imma-
ture DC and macrophages present self and innocuous antigens
to T cells in a subimmunogenic context. Recognition of cognate
antigen in the absence of costimulation causes effector T cells to die,
become anergic, or convert into regulatory T cells. Thereby, antigen
presentation by nonactivated mononuclear phagocytes contributes
to the steady-state maintenance of self-tolerance. A second “class”
of myeloid regulatory cell arises as a consequence of persistent stim-
ulation with proinflammatory mediators. Such activation-induced
myeloid suppressor cells presumably serve as counterregulators that
limit self-injurious inflammatory responses. Activation-induced
myeloid regulatory cells are phenotypically diverse and operate
through a variety of mechanisms, including production of T cell-
suppressive soluble factors, receptor-mediated killing of effector T
cells, and the activation-dependent induction of Tregs.
in tissues initiates the acute inflammatory cascade, including
further recruitment of inflammatory monocytes from blood,
often resulting in secondary tissue injury. Activated DC
rapidly migrate into lymphoid tissues to stimulate adaptive
immune responses, a key property of inflammatory DC.
Importantly, the acute inflammatory reaction is generally
self-limiting, which is partly due to repetitively and intensely
stimulated mononuclear phagocytes switching to an anti-
inflammatory mode. Hence, macrophages and DC can show
suppressor functions both as immature cells and as poststim-
ulatory antigen-presenting cells.
3. tolDC and Mregs as Therapeutic Cell
Product to Restore Tolerance
The essential role of mononuclear phagocytes in the induc-
tion and maintenance of transplant tolerance, especially the
many demonstrations that this activity could be adoptively
transferred with purified DC or macrophage populations,
spurred great interest in the prospect of using tolAPC to sup-
press pathogenic immune responses [17, 18]. Given the phe-
notypic plasticity of mononuclear phagocytes, it is perhaps
unsurprising that a wide selection of alternative monocyte-
derived cell types has been developed as potentially thera-
peutic cell types [19]. Most attention has focused on treating
DC to drive them into a state of arrested immaturity;
however, other groups are currently developing therapeutic
cell products based on poststimulatory monocyte-derived
suppressor cell types or myeloid-derived suppressor cells
from early monocyte progenitors (Figure 3).
While the “default” function of DC is to induce tolerance,
activated DC have the ability to promote destructive T cell
responses.Hence it is clear thatmaintainingDC in activation-
resistant state is an absolute prerequisite for tolDC therapy.
tolDC can be defined as a maturation-resistant cell with an
immature or semimature phenotype (e.g., low expression of
costimulatorymolecules) and stable prominent expression of
anti-inflammatory molecules and low expression of proin-
flammatory cytokines. In order to achieve this, several biolog-
ical and pharmacological agents have been evaluated to gen-
erate tolDC in vitro [20–25]. Since nuclear translocation of
the nuclear factor kappa-light chain-enhancer of activated B
cells (NF-𝜅B) is one of the major cellular processes following
stimulation with a proinflammatory mediator, several agents
that block this pathway and consequently the maturation
process of DC have been tested to generate tolDC in vitro,
including the NF-𝜅B inhibitor, Bay11-7082, vitamin D
3,
dex-
amethasone, or IL-10 [26–28]. In addition vitaminD
3
has also
been demonstrated to interfere with cellular metabolism. It
counteracts the metabolic shift towards higher glycolysis and
progressive loss of mitochondrial oxidative phosphorylation
following inflammatory activation [29]. Furthermore, DC
can be modified genetically by knocking out immunogenic
functions or by inserting tolerogenic characteristics. Overall,
tolDC generated in vitro using these agents have been
demonstrated to reduce symptoms of established AID or to
prevent the rejection of transplanted tissues in experimental
animal models [30, 31].These promising outcomes have been
instrumental in the development of tolDC therapy for the
treatment of human AID and prevention of transplant rejec-
tion. Hereunto, a number of methods to generate tolDC in
vitro have been translated according to Good Manufacturing
Practice (GMP) for clinical use in the last 15 years.
Another clinically advanced example of an activation-
induced monocyte-derived suppressor cell is Mreg [32].
Through their adherence to plastic surfaces, exposure to
serum components, and stimulation with IFN-𝛾, monocytes
are matured to suppressive macrophages that act through
indoleamine 2,3-dioxygenase- (IDO-) dependent mecha-
nisms [13]. Mregs express CD86 andHLA-DR, as well as high
levels of othermaturation-associatedmarkers, like CD274. At
least in vitro, human Mregs are capable of deleting activated
T cells, suppressing T cell proliferation, and driving naı¨ve T
cells to become induced Tregs [33].
4. tolAPC-Based Clinical Trials
Several preparations of tolAPC have been tested in phase I
clinical trials. Trials with autologous tolDC have been com-
pleted for T1D (USA) [12], RA (Australia [10], UK, and South
Korea [34]) and Crohn’s disease (Spain) [11] (Table 1). So far
the results are highly encouraging from a safety standpoint,
since none of the trials have found any major concerns
that will prevent further testing. tolDC therapy was well
tolerated by the patients, and, importantly, autoimmunity in
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Myeloid-derived suppressor cell (MDSC)
Activated 
monocytes
Arrested 
immaturity
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Regulatory macrophages (Mreg)
Glucocorticoid and vit. D3 DC
ATDC
Monocytic 
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Rapa-DC
DC-10
CD11b+ CD14+ CD163− CD80low CD86low HLA-DRlow
CD11b+ CD14++ CD163++ CD80+ CD86+ HLA-DR++
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CD80−/low CD86−/low HLA-DR−/low
CD11b+ CD14−/low CD33+ CD34+
CD11b+ CD14−/low CD80−/low CD86+ HLA-DR+
Figure 3: tolAPC types being developed as immunosuppressive cell-based medicinal products. The spectrum of myeloid regulatory cell
products currently being developed asmedicinal products is diverse, so it is valuable to categorise them as cells in arrested states of immaturity
(tolDC), activation-induced suppressor cells, or myeloid-derived suppressor cells. Examples of different tolDC products are depicted.
treated patients was not enhanced. Further phase I tolDC
trials are underway in MS (Spain, Belgium, and Russia),
neuromyelitis optica (Spain), T1D (The Netherlands), and
kidney transplantation (France). Furthermore, phase II trial
with tolDC in T1D patients (USA)will start to recruit patients
imminently. Mregs containing cell products have now been
administered as an adjunct immunosuppressive therapy to
more than 20 kidney transplant recipients with promising
early results [13, 35, 36]. This therapeutic approach is now
being extended in the One Study [37].
5. Collaborative Efforts to Overcome
Limitations in tolAPC Therapy
As summarized above, several tolAPC products have been or
are being tested in clinical trials. Due to the manufacturing
and regulatory complexities associated with initiating a cellu-
lar therapy, relatively few groups are preparing or conducting
trials with cell-based tolerance-inducing therapies (CTT)
in Europe or worldwide. Specific meetings or forums are
lacking, sincemost scientists attend disease-specificmeetings
or general immunology meetings in which the CTT field,
including tolAPC, is underrepresented. Research groups
working in kidney transplantation recently initiated a joint
initiative in CTT (“One Study” EU consortium), aiming
to evaluate CTT in living-donor kidney transplantation;
alternatively, many other groups working in other types of
organ transplantation or AID are developing their projects
independently. Due to this widely distributed and limited
action in CTT, joint action is needed to integrate experi-
ences, to share results, and to discuss the strategies to go
forward with clinical applications of new clinical trials. To
achieve this the EU COST consortium A FACTT (action to
focus and accelerate cell-based tolerance-inducing therapies)
was initiated in 2014 to accelerate the development and
implementation of all CTT, including tolDC and Mreg,
by creating a forum for the exchange and integration of
knowledge and expertise. This is the first European initiative
to bring together different disciplines in the context of human
immune tolerance with the main objective to accelerate and
advance the clinical application of CTT treatment of AID,
allergy, and prevention of graft rejection.
Regarding tolAPC current limitations of this therapy are
related to both the production process and evaluation of the
clinical trials, which are intended to provide information
for the postulated mechanism(s) of action. The first steps
to be undertaken by the A FACTT consortium will help
move the tolDC field forward by addressing key issues in a
collaborative effort between different labs and interests. The
most important ones of these issues are discussed below.
5.1. Comparison of tolDC Production Protocols. One out-
standing issue within the cellular therapies field is the
variation in themethods used for extraction, production, and
use of cells for therapeutic purposes. Differentmethodologies
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make it difficult to directly compare different cell products,
therefore bringing uncertainty when ultimately comparing
final efficacy and safety results. One solution to this problem
is to define a set of standard protocols; however, this approach
would be difficult since it would require substantial changes
to existing methods from many laboratories. As part of the
A FACTT project, we are defining a less radical approach
of providing a standard reporting framework. We call this
MITAP (Minimum Information about Tolerogenic Antigen-
Presenting Cells). These guidelines make differences and
similarities of approaches immediately clear and transparent.
We believe that this approach has a much higher chance
of being used by the CTT community as it also provides
a checklist for authors when, for example, describing their
methods in papers; MITAP makes their jobs easier rather
than adding to the burden of scientific publication. We have
testedMITAPwithin the A FACTT community and are ready
to release the final version within the immediate future.
5.2. Consensus on Functional Quality Control Parameters.
In general, clinically applicable tolDC can be defined as
a maturation-resistant cell with MHC II expression and
an immature or semimature phenotype (low or limited
expression of CD80, CD83, and CD86) and stable promi-
nent expression of anti-inflammatory membrane molecules
and/or secreted products and low expression of proinflam-
matory cytokines, even in presence of environmental proin-
flammatory signals. Another limitation is that there is no con-
sensus on how to determine the “tolerogenicity” (potency) of
the tolDC product, given that tolerance can be achieved by
different mechanisms, hereby restricting standardisation of
functional quality control (QC) parameter(s), rendering the
comparison between products in terms of functionality and
safety between different laboratories difficult.
Often functional assays such as a suppression assay or
an allostimulatory capacity assay are considered as potency
assay. However it has to be taken into consideration that this
type of assays is slow and not very precise. Therefore the use
of suitable “surrogate” potency markers has to be regarded,
for example, the release of inhibitorymolecules (IL-10, TGF𝛽,
and IDO), the surface expression of certain surface markers,
or even the lack of certain molecules. For this insight into the
tolDC products and their mechanism of tolerance induction
is important.
Understanding the fundamental biological relationships
between alternative tolDC products is a key objective of
the A FACTT consortium. Appreciating the similarities and
dissimilarities between cell types and how these differences
dictate the pharmacological properties of those cells as
therapeutic agents is critical to the efficient advancement
of the field. Via A FACTT we aim to discuss and share
experience to create a consensus and position on a minimal
set of functionalQCparameters, again documented using the
above-mentioned MITAP, hereby making it possible in the
future to compare different tolDC approaches.
5.3. Harmonization of Immunomonitoring. Interpretation of
the results obtained from immunomonitoring of tolAPC
trials is a difficult task due to the variety of methods and
protocols available to detect specific T cell responses.The lack
of harmonized immunomonitoring protocols for analysis of
treated patients makes it difficult to compare outcome of
individual trials, decelerating the potential progress of the
field.
The capability of tolAPC therapy to suppress pathogenic
T cell responses in vivo needs to be monitored before and
after administration of the tolerance-inducing cell products
to determine the effects of tolAPC therapy on the immune
system and to correlate these effects with clinical outcomes.
Limitations in harmonization of immunomonitoring are due
to limited insight into in vivo mechanisms of tolerance
and lack of proven biomarkers. A FACTT aims to create
a consensus and position on relevant immunomonitoring
assays and will emphasize the use of minimal information
models to describe them. To achieve harmonization for
the performance of specific flow-cytometric and functional
assays, standardised methods, panels, and sampling condi-
tionswill be recommended through publications and focused
workshops.
5.4. Regulations. tolAPC are substantially modified cells
and therefore must be classified in Europe as somatic cell
advanced therapymedicinal products (ATMP).This has been
imposed by the Regulation (EC) number 1394/2007 of the
European Parliament and of the Council [38]. The most
important consequence of this approach is that ATMP are
treated similarly to other biological medicinal products and
not as cells. Marketing authorisation approval (MAA) for
such products is centralized via European Medicinal Agency
and the path to offer ATMP to the patients is substantially
longer when compared to cells for transplantation or trans-
fusion/blood products, as they must be checked in a series
of preclinical tests and in subsequent expensive clinical trials
similarly to other classes of drugs. In some cases, this path
is difficult to achieve as the cells cannot be defined to the
level possible for small-molecule or even biological drugs.
Although this is recognized by regulatory bodies, it adds to
already very high standards of GMP required to produce
cells for clinical use. Since 2007, when regulations were
introduced, only five ATMP hold centralized MAA (none
of them tolDC) in Europe, which illustrates difficultness
of the regulations. Elusive promise of financial reward and
very specific expertise necessary to develop ATMP distracts
big pharma from investing in this branch of medicine and
therefore academic hospitals, universities, and small-sized
enterprises (usually academia-based) with limited resources
are still the main manufacturers of ATMP. For obvious
economic reasons, the regulations create significant hurdles
for such organizations and significantly delay the translation
of tolDC application.
A FACTT aims to streamline the interaction with the
regulatory authorities, in which the opinion and experience
of leading groups in CTT are represented, via discussions
with authorities and via position papers. Hereby, A FACTT
aims to create awareness that therapeutic cells have different
mechanisms of action and a different safety profile compared
to conventional chemical drugs and thus need unconven-
tional regulatory requirements [39]. Furthermore by sharing
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preclinical data necessary for the Investigational Medicinal
Product Dossier, A FACTT aims to avoid effort duplication
for preclinical studies.
6. Conclusion
Overall, by creating a forum for researchers and clinicians
working in the field of CTT therapy, experiences should be
shared to enable upcoming trials based on the experience
gained in previous trials. This approach saves money in
duplicating work and will likely optimize outcomes for future
trials. Expertise from ongoing or completed tolDC trials will
be shared by our partners with laboratories preparing for
new CTT (e.g., through short-term scientific missions). We
envisage that the A FACTT collaborative effort will be an
important step to accelerate the implementation of CTT in
the clinic.
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